ArticlePDF Available

Abstract

Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus responsible for painful disabling polyarthritis, undergoing re-emergence in the Indian Ocean and the Asian continent. Travelling and changing patterns of vector distribution, and abundance due to climate changes, make CHIKV a global threat without effective control strategies. One approach to reduce the CHIKV burden is the development of a vaccine. Virus-like particles (VLPs) are a safe and highly effective class of subunit vaccines that mimic the overall structure of virus particles. Accordingly, we aim to produce CHIKV VLPs in a baculovirus-insect cell system, well known for allowing high yields of recombinant protein expression, to be used as a vaccine preparation.
Expression of Chikungunya virus-like particles
R. A. Velez*, A. P. Alves de Matos**, R. Parreira*, J. Piedade, B. Matos***, C. Correia*** and A.
Esteves*
* Grupo de Virologia, Unidade de Microbiologia Médica, UPMM, Instituto de Higiene e Medicina
Tropical, UNA, 1349-008 Lisboa, Portugal
** Centro Hospitalar de Lisboa Central – HCC, Serviço de Anatomia Patológica, R. da Beneficência
8, 1069-166 Lisboa and Centro de Estudos do Ambiente e do Mar (CESAM) – Faculdade de Ciências
da Universidade de Lisboa, Campo Grande, 1149-016, Lisboa, Portugal
*** Centro Hospitalar de Lisboa Central – HCC, Serviço de Anatomia Patológica, R. da Beneficência
8, 1069-166 Lisboa, Portugal
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus responsible for painful disabling
polyarthritis, undergoing re-emergence in the Indian Ocean and the Asian continent[1]. Travelling and
changing patterns of vector distribution, and abundance due to climate changes, make CHIKV a global
threat without effective control strategies. One approach to reduce the CHIKV burden is the
development of a vaccine. Virus-like particles (VLPs) are a safe and highly effective class of subunit
vaccines that mimic the overall structure of virus particles. Accordingly, we aim to produce CHIKV
VLPs in a baculovirus-insect cell system, well known for allowing high yields of recombinant protein
expression, to be used as a vaccine preparation.
The ORF coding the CHIKV structural proteins is 3.8 kb long, and therefore there is a chance for
generating recombinant baculoviruses with spurious stop codons leading to truncated polyproteins. To
minimize this possibility, the CHIKV structural sequence was amplified by RT-PCR as a SacI-NotI
fragment, and cloned into the mammalian expression vector pLEXm (a gift from R. Aricescu, Oxford,
UK) downstream the strong chick beta actin promoter. Several clones with the correct insert size were
obtained and transfected into HEK293T cells using polyethylenimine as the transfection reagent[2].
Five recombinant vectors were shown to express CHIKV proteins by immunofluorescence (IFA) and
Western blotting (WB) analyses using a polyclonal serum against CHIKV (Figure 1A). One clone,
with high levels of IFA labelling, coded for a truncated viral polyprotein (WB data), while three
others, with a lower IFA signal, originated low levels of viral envelope glycoproteins correctly
processed. Cells transfected with clone p67 showed IFA staining and viral glycoprotein pattern on WB
similar to cells infected with CHIKV (Figure 1A compare lanes I and p67). Precipitation of clarified
cell culture medium from p67 transfected cells, and from CHIKV infected cells, with PEG 8000
generated pellets with an identical content of viral glycoproteins on WB (Figure 1B). These results
strongly indicate that p67 transfected cells express CHIKV structural proteins that are assembled into
VLPs. Transmission electron microscopy analysis of p67 transfected cells (Figure 3) confirmed the
assembly of VLPs with a morphology similar to the virus particles produced in CHIKV infected cells
(Figure 2). Quite unexpectedly, transfected cells expressing only the CHIKV structural proteins
(Figure 3) exhibit cytoplasmic membrane rearrangements similar to the vesicle arrays observed in
CHIKV infected cells (Figure 2) and reported as induced by non-structural viral proteins. In
conclusion, p67 will be used as a source of CHIKV structural genes for construction of recombinant
baculoviruses.
References
1. Townson H. and Nathan M.B., Trans R Soc Trp Med Hyg 102: 308-309, 2008
2. Aricescu et al., Acta Cryst. D62: 1243-1250, 2006
59
doi:10.1017/S1431927612012950
Microsc. Microanal. 18 (Suppl 5), 2012
© Microscopy Society of America 2012
Figure 1. Western blot analysis of CHIKV proteins. Cells were infected with CHIKV (I) or transfected
with the indicated recombinant vectors. Cell lysates (A) and PEG-pelleted supernatants (B) were
probed with mouse anti-CHIKV polyclonal sera. The predicted viral proteins (E1, E2 and p62) are
indicated. NI, non-infected cells. V, cells transfected with the pLEXm vector alone.
Figure 2. HEK 293T cells infected with CHIKV
for 24h. a) Array of vesicles in the cytoplasm of
the infected cells. b) Extracellular CHIKV
particles (arrows)
Figure 3. HEK 293T cells transfected with
recombinant plasmid clone p67 for 48h. a)
Array of vesicles in the cytoplasm of the
transfected cells. b) Extracellular CHIKV VLPs
(arrows).
A
B
I V
p
28
p
45
p
67
p
76 I NI V
p
28
p
45
p
62
p
67
p
69
p
76
E1/E2
E1/E2
p62
Microsc. Microanal. 18 (Suppl 5), 201260
... Influenza VLPs are possibly the most studied enveloped VLPs (Kang et al., 2012), commonly consisting of matrix M1 proteins and with glycoprotein hemagglutinin (HA) and/or neuraminidase (NA) embedded in the lipid bilayer. Human immunodeficiency virus (HIV) VLPs (Buonaguro et al., 2013) and Ebola virus VLPs have also been well reported, with recent attention on VLPs of Chikungunya virus (Metz et al., 2013;Velez et al., 2012) and Nipah virus (Walpita et al., 2011). ...
Article
Virus-like particle (VLP) technology seeks to harness the optimally tuned immunostimulatory properties of natural viruses while omitting the infectious trait. VLPs that assemble from a single protein have been shown to be safe and highly efficacious in humans, and highly profitable. VLPs emerging from basic research possess varying levels of complexity and comprise single or multiple proteins, with or without a lipid membrane. Complex VLP assembly is traditionally orchestrated within cells using black-box approaches, which are appropriate when knowledge and control over assembly are limited. Recovery challenges including those of adherent and intracellular contaminants must then be addressed. Recent commercial VLPs variously incorporate steps that include VLP in vitro assembly to address these problems robustly, but at the expense of process complexity. Increasing research activity and translation opportunity necessitate bioengineering advances and new bioprocessing modalities for efficient and cost-effective production of VLPs. Emerging approaches are necessarily multi-scale and multi-disciplinary, encompassing diverse fields from computational design of molecules to new macro-scale purification materials. In this review, we highlight historical and emerging VLP vaccine approaches. We overview approaches that seek to specifically engineer a desirable immune response through modular VLP design, and those that seek to improve bioprocess efficiency through inhibition of intracellular assembly to allow optimal use of existing purification technologies prior to cell-free VLP assembly. Greater understanding of VLP assembly and increased interdisciplinary activity will see enormous progress in VLP technology over the coming decade, driven by clear translational opportunity. Biotechnol. Bioeng. 2013;9999: 1-16. © 2013 Wiley Periodicals, Inc.
... 50 Other promising CHIKV vaccine candidates that depend on virus-like particles are in the early stages of preclinical development. 51,52 A successful viruslike particle vaccine based on viral structural proteins was tested on non-human primates and was found to produce neutralizing antibodies that protect against viremia after high-dose challenge. When these antibodies were transferred into an immunodeficient host (a mice), the host was protected indicating a passive immunity. ...
Article
Chikungunya virus is an emerging arbovirus that is widespread in tropical regions and is spreading quickly to temperate climates with recent epidemics in Africa and Asia, and documented outbreaks in Europe and the Americas. It is having an increasingly major impact on humankind, with potentially life-threatening and debilitating arthritis. There is no treatment available, and only in the last 24 months have lead compounds for development as potential therapeutics been reported. This perspective discusses the chikungunya virus as a significant, new emerging topic for medicinal chemistry, highlighting the key viral target proteins and their molecular functions that can be used in drug design, as well as the most important ongoing developments for anti-chikungunya virus research. It represents a complete picture of the current medicinal chemistry of chikungunya, supporting the development of chemotherapeutics through drug discovery and design targeting this virus.
Article
As mimicking natural virus structures, virus-like particles (VLPs) have evolved to become a widely accepted technology used for humans which are safe, highly efficacious and profitable. Several remarkable advantages have been achieved to revolutionize the molecule delivery for diverse applications in nanotechnology, biotechnology, and medicine. Here, we review the rational structure design, manufacturing process, functionalization strategy, and emerging applications of VLPs. The situation and challenges in the VLP engineering, the key development orientation, and future applications have been discussed. To develop a good VLP design concept, the virus/VLPhost interactions need to be examined and the screening methods of the VLP stabilization factors need to be established. The functionalization toolbox can be expanded to fabricate smart, robust and multifunctional VLPs. Novel robust VLP manufacturing platforms are required to deliver vaccines in resource-poor regions with a significant reduction in the production time and cost. The future applications of VLPs are always driven by the development of emerging technologies and new requirements of modern life.
Article
Chikungunya, an arboviral disease transmitted by Aedes mosquitoes, has recently increased dramatically in incidence and geographic extent. Large outbreaks have affected islands of the Indian Ocean, India and other parts of South and Southeast Asia, Africa and most recently Italy. International travellers have disseminated new strains of the virus, some into regions from which chikungunya has hitherto been absent. In parallel, over the past 30 years international trade has resulted in the spread of A. albopictus from its original range in Asia, to all continents but Antarctica, thereby extending the geographic area over which transmission can occur.
  • Aricescu
Aricescu et al., Acta Cryst. D62: 1243-1250, 2006
  • H Townson
  • M B Nathan
Townson H. and Nathan M.B., Trans R Soc Trp Med Hyg 102: 308-309, 2008